Mytillocactus (cactaecea) : botanical, agronomic, physichemical and chemical characteristics of fruits

Au Mexique, la production de fruits de Myrtillocactus est importante, pourtant ceux-ci sont souvent sous-utilisés. Bien qu'ils soient essentiellement exploités pour leur potentiel de colorants alimentaires, les fruits mériteraient davantage d'attention quant à leurs autres propriétés pour l'alimentation, mais les informations sur leur composition physico-chimique sont rares. Afin de disposer d'éléments de base pour le développement de la culture de Myrtillocactus, nous avons étudié les informations accessibles à ce jour. Description botanique. Quatre espèces de Myrtillocactus ont été identifiées et rapportées dans la littérature. Elles diffèrent par la forme, la couleur, et d'autres caractéristiques phénotypiques. Au Mexique, l'espèce prédominante est M. geometrizans, mais M. schenckii se développe également abondamment dans toutes les terres arides et semi-arides du pays. Les analyses cytologiques effectuées sur M. geometrizans ont montré que la plante était diploïde (2n = 22). Aspects agronomiques. Le genre Myrtillocactus appartient à la famille des cactacées. En raison de son métabolisme crassulacéen acide, la plante peut se développer dans les montagnes arides et semi-arides du Mexique. Les espèces de Myrtillocactus sont propagées asexuellement par explants ou par clonage. En conditions contrôlées, la micropropagation in vitro d'explants apicaux et basaux donne de hauts rendements. Pour la culture, une attention particulière doit être apportée aux températures hivernales minimales. Description des fruits et caractérisation biochimique. Le fruit comestible est globulaire, avec un diamètre atteignant 1,5 cm. La pulpe est colloïdale, sa couleur va du rougeoyant au rouge bleuâtre. La caractérisation chimique a principalement porté sur la composition en bétalaines, dont les composés prédominants sont la bétanine et les bétaxanthines. La teneur en bétalaines serait de 2,3 mg ·100 g -1 de pulpe. Le colorant semble être plus stable que celui des betteraves rouges. Consommation humaine et importance commerciale. Pendant la saison de production (juin à septembre), les fruits sont trouvés sur tous les marchés de leur lieu de production. Ils sont mangés frais ou transformés. La commercialisation du fruit est limitée principalement aux zones de production rurales dans certains états du Mexique. Conclusions. Notre synthèse a établi que les informations publiées sur Myrtillocactus étaient rares et incomplètes. La plante est sous utilisée, en dépit de ses propriétés alimentaires et de son potentiel commercial. Comme les espèces de Myrtillocactus s'adaptent facilement dans des conditions de grande sécheresse, elles mériteraient de faire l'objet de beaucoup plus de recherche (Résumé d'auteur

MERCADOTECNIA SOCIAL Y DE SERVICIOS

ANTOLOGI

ESTRATEGIAS DE VENTAS Y TECNICAS DE NEGOCIACION

ANTOLOGI

Factores de riesgo de la fibrilación auricular en el Hospital Provincial General Docente Riobamba

The research process developed was observational, descriptive, transversal. 52 medical records of patients with AF were reviewed in the Internal Medicine service of the General Hospital of Riobamba-Ecuador in the period from May 1, 2017 to April 25, 2018. The chosen medical records were grouped into two sets: the first consisting of patients with clinical manifestations of AF and with electrocardiographic diagnosis of this arrhythmia (n = 38) ; the second one integrated the asymptomatic or slightly symptomatic diagnosed by electrocardiogram (n = 14). The results obtained indicated that 73.08% of the patients were symptomatic. Those over 70 years of age predominated in the study. Arterial hypertension and heart failure were the main risk factors present in the study population. The chi-square statistical test allowed to establish the existence of a significant relationship, between the presence of risk factors and the appearance of the clinical manifestations corresponding to AF, when a p value <0.05 (0.042) was obtained.El proceso investigativo desarrollado fue de tipo observacional, descriptivo, transversal; para lo que se revisaron 52 historias clínicas de pacientes con FA, en el servicio de Medicina Interna del Hospital Provincial General Docente de Riobamba, Ecuador; en el período comprendido desde el 1 de mayo del 2017 hasta el 25 de abril del 2018. Las historias seleccionadas fueron agrupadas en dos conjuntos: el primero compuesto por pacientes con manifestaciones clínicas de FA y con diagnóstico electrocardiográfico de esta arritmia (n=38); mientras que el segundo, integró a los asintomáticos o levemente sintomáticos diagnosticados por electrocardiograma (n=14). Los resultados obtenidos indicaron que el 73,08% de los pacientes estaban sintomáticos. Los mayores de 70 años de edad predominaron en el estudio. La hipertensión arterial y la insuficiencia cardíaca resultaron los principales factores de riesgo presentes en la población estudiada. La prueba estadística el chi cuadrado permitió establecer la existencia de una relación significativa, entre la presencia de factores de riesgo y la aparición de las manifestaciones clínicas correspondientes a la FA, al obtenerse un valor p<0,05 (0,042)

Postoperative Pain in Pediatrics

Postoperative pain in pediatrics is a common concern for both parents and healthcare professionals. Children who experience pain after surgery can present with several complications, including nausea, vomiting, breathing difficulties, sleep disturbances, and decreased physical activity. In addition, untreated pain can have long-term effects on children’s emotional and psychological well-being. It is important to recognize that children may experience pain differently than adults and, therefore, need a personalized treatment approach. Evaluation and management of postoperative pain in pediatrics should be based on the child’s age, the type of surgery, and the severity of pain. Several treatment options are available, including oral, intravenous, and epidural analgesics, as well as non-pharmacological techniques such as relaxation and distraction. Prevention of postoperative pain is also important and can be achieved through the administration of analgesics prior to surgery and early postoperative care

Concurrent La and A-site Vacancy Doping Modulates the Thermoelectric Response of SrTiO3. Experimental and Computational Evidence

To help understand the factors controlling the performance of one of the most promising n-type oxide thermoelectric SrTiO3, we need to explore structural control at the atomic level. In Sr1–xLa2x/3TiO3 ceramics (0.0 ≤ x ≤ 0.9), we determined that the thermal conductivity can be reduced and controlled through an interplay of La-substitution and A-site vacancies and the formation of a layered structure. The decrease in thermal conductivity with La and A-site vacancy substitution dominates the trend in the overall thermoelectric response. The maximum dimensionless figure of merit is 0.27 at 1070 K for composition x = 0.50 where half of the A-sites are occupied with La and vacancies. Atomic resolution Z-contrast imaging and atomic scale chemical analysis show that as the La content increases, A-site vacancies initially distribute randomly (x < 0.3), then cluster (x ≈ 0.5), and finally form layers (x = 0.9). The layering is accompanied by a structural phase transformation from cubic to orthorhombic and the formation of 90° rotational twins and antiphase boundaries, leading to the formation of localized supercells. The distribution of La and A-site vacancies contributes to a nonuniform distribution of atomic scale features. This combination induces temperature stable behavior in the material and reduces thermal conductivity, an important route to enhancement of the thermoelectric performance. A computational study confirmed that the thermal conductivity of SrTiO3 is lowered by the introduction of La and A-site vacancies as shown by the experiments. The modeling supports that a critical mass of A-site vacancies is needed to reduce thermal conductivity and that the arrangement of La, Sr, and A-site vacancies has a significant impact on thermal conductivity only at high La concentration

Measurement of charm production at central rapidity in proton-proton collisions at s=2.76\sqrt{s} = 2.76 TeV

The $p_{\rm T}$-differential production cross sections of the prompt (B feed-down subtracted) charmed mesons D$^0$, D$^+$, and D$^{*+}$ in the rapidity range $|y|<0.5$, and for transverse momentum $1< p_{\rm T} <12$ GeV/$c$, were measured in proton-proton collisions at $\sqrt{s} = 2.76$ TeV with the ALICE detector at the Large Hadron Collider. The analysis exploited the hadronic decays D$^0 \rightarrow$K$\pi$, D$^+ \rightarrow$K$\pi\pi$, D$^{*+} \rightarrow$D$^0\pi$, and their charge conjugates, and was performed on a $L_{\rm int} = 1.1$ nb$^{-1}$ event sample collected in 2011 with a minimum-bias trigger. The total charm production cross section at $\sqrt{s} = 2.76$ TeV and at 7 TeV was evaluated by extrapolating to the full phase space the $p_{\rm T}$-differential production cross sections at $\sqrt{s} = 2.76$ TeV and our previous measurements at $\sqrt{s} = 7$ TeV. The results were compared to existing measurements and to perturbative-QCD calculations. The fraction of cdbar D mesons produced in a vector state was also determined.Comment: 20 pages, 5 captioned figures, 4 tables, authors from page 15, published version, figures at http://aliceinfo.cern.ch/ArtSubmission/node/307

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline